Defending against Viral Threats: Global Antiviral Drugs Market to Reach $74.75 Billion by 2028

Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Antiviral Drugs Market (2023-2028) by Drug Type, Disease, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to's offering.

The Global Antiviral Drugs Market is estimated to be USD 55.36 Bn in 2023 and is expected to reach USD 74.75 Bn by 2028, growing at a CAGR of 6.19%.

Antiviral medications are those created specifically to target and prevent the spread and replication of viruses within the human body. They are essential for managing and treating viral infections. These medications function by either directly attacking the virus or preventing it from proliferating and infecting healthy cells. Antiviral medications are essential tools for both preventing and treating viral infections.

They assist in symptom relief, lessen the severity and length of illnesses, and enhance patient outcomes. Global efforts to combat viral diseases are aided by ongoing research and development in the field of antiviral therapy, which is expanding the options for effective treatment against various viral infections.

The demand for antiviral medications is anticipated to rise due to the rising prevalence of viral infections like HIV, Herpes, Influenza, and others over the forecast period. Global demand for antiviral medications has significantly increased as a result of the COVID-19 pandemic. The need for broad-spectrum antiviral medications has increased due to the management of novel coronaviruses.

For the treatment of COVID-19, remdesivir, favipiravir, oseltamivir, and other combination medications are frequently prescribed. Additionally, governments are providing pharmaceutical companies with more funding to create cutting-edge treatments for COVID-19. Additionally, several pharmaceutical firms are concentrating on developing new drugs to offer patients better patient outcomes and more effective treatments.

An increase in the reported rate of viral disorders is driving the global market share for anti-viral medications. The market for antiviral drugs is also anticipated to be driven by an increase in R&D activities and the expansion of more recent and updated information, such as vaccinations and combined therapy. Time is needed and the market revenue and profit are constrained in creating a safe, effective, and targeted antiviral.

Potential viral pandemics highlight the need for rapid, widespread deployment of broad-spectrum antiviral drugs, like direct-acting antivirals, to stop viral spread until adequate vaccines are developed. The market for antiviral medications is also anticipated to be constrained by growing knowledge of infection prevention strategies and vaccination accessibility.

Numerous novel drugs are anticipated to be developed during the forecast period as a result of increased partnerships for antiviral drug development and manufacturing. The market's top rivals are working together to develop cutting-edge therapies that will lessen the virus strain that antiviral medications can treat.

The market for antiviral medications is expanding as a result of developments in science and technology. A better understanding of viral replication mechanisms has been made possible by advances in genomics, proteomics, and molecular biology, opening up new avenues for the development of therapeutic interventions. As a result, more potent and specific antiviral therapies have been created.

The global market for antiviral medications has bright future prospects. There is a lot of potential in the ongoing developments in antiviral drug research and development, including investigating novel drug targets and creating broad-spectrum antivirals. Additionally, developing novel technologies like CRISPR-based therapeutics and RNA interference (RNAi) opens up new possibilities for discovering antiviral drugs.

The successful development and widespread use of COVID-19 vaccines are further evidence of the growing emphasis on viral disease prevention through vaccination, which is likely to affect the demand for antiviral medications. Antivirals can be used as additional therapies or as preventative measures in high-risk populations, enhancing the function of vaccines in the management of disease.

Market Dynamics:


  • Growing Occurrence of Viral Diseases Such as HIV, Hepatitis, and Influenza
  • Rising Government and Private Sector Expenditure in The Development of Antiviral Drugs
  • Extensive Geriatric Population Coupled with Healthcare Awareness Among Consumers


  • Stringent Government Regulations for the Development of New Drugs


  • Burgeoning Research and Development in the Production of Vaccines for Numerous Viral Diseases
  • Extensive Formulations to Develop HIV Vaccines


  • Increasing Awareness of Preventative Treatments

Companies Mentioned:

  • Abbott Laboratories
  • AbbVie, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ag
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Pfizer Corp.

Key Attributes:

Report AttributeDetails
No. of Pages155
Forecast Period2023 - 2028
Estimated Market Value (USD) in 2023$55.36 Billion
Forecasted Market Value (USD) by 2028$74.75 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global Antiviral Drugs Market

Contact Data